Kantarjian et al developed a model for predicting the chances that a patient with Philadelphia-chromosome positive chronic myeloid leukemia (CML) in the chronic phase. The authors are from the MD Anderson Cancer Center at the University of Texas Houston.
Criteria for complete cytogenetic response: 0% Ph chromosome positive by standard cytogenetic analysis (not FISH)
Parameters:
(1) percent of cells positive for Philadelphia chromosome at start of therapy
(2) platelet count at start of therapy
|
Parameter |
Finding |
Points |
|
percent of cells positive for Philadelphia chromosome |
<= 90% |
0 |
|
|
> 90% |
1 |
|
platelet count |
<= 450,000 per µL |
0 |
|
|
> 450,000 per µL |
1 |
risk score =
= SUM(points for both parameters)
Interpretation:
• minimum score: 0
• maximum score: 2
• The higher the score the less likely that the patient will have a complete cytogenetic response.
|
Risk Score |
Risk Group |
Complete Cyto-genetic Response |
Survival at 4 Years |
|
0 |
good |
94% |
94% |
|
1 |
fair (intermediate) |
58% |
88% |
|
2 |
poor |
39% |
73% |
Purpose: To determine the chances of having a complete cytogenetic response following imatinib mesylate therapy in a Philadelphia chrosome positive CML in chronic phase.
Specialty: Hematology Oncology
Objective: risk factors
ICD-10: C92.1,
